| Size | Price | Stock | Qty |
|---|---|---|---|
| 1mg |
|
||
| 5mg |
|
||
| 1g | |||
| Other Sizes |
| Targets |
Cyclo(Arg-Ala-Asp-(D-Tyr)-Lys) does not have a defined biological target as a therapeutic agent. It serves as a control peptide for c(RGDyK), which targets integrin receptors such as αvβ3. The RAD sequence does not bind integrins with high affinity, making this peptide a useful negative control for distinguishing specific integrin-mediated effects from non-specific peptide effects. It is not characterized for direct pharmacological activity.
|
|---|---|
| ln Vitro |
As a control peptide for c(RGDyK), Cyclo(Arg-Ala-Asp-(D-Tyr)-Lys) does not exhibit significant biological activity in integrin-binding assays. It is used to demonstrate the specificity of c(RGDyK) effects by showing that the RAD sequence does not inhibit integrin-mediated cell adhesion or signaling. Its in vitro activity is primarily defined by its lack of activity, serving as a baseline for experimental comparisons.
|
| ln Vivo |
Cyclo(Arg-Ala-Asp-(D-Tyr)-Lys) is not used for in vivo pharmacological activity assessment as a therapeutic agent. It may be used in animal studies as a negative control peptide to validate the specificity of c(RGDyK)-mediated effects. However, its primary application is in vitro as a control reagent. It is not intended to be administered for therapeutic purposes.
|
| Enzyme Assay |
As a control peptide, Cyclo(Arg-Ala-Asp-(D-Tyr)-Lys) is not typically used in enzyme/receptor binding assays as a test compound. It may be employed in competitive binding assays alongside c(RGDyK) to demonstrate receptor specificity. The peptide is incubated with integrin-containing preparations, and binding is assessed using standard biochemical methods such as ELISA, surface plasmon resonance, or fluorescence polarization.
|
| Cell Assay |
Cyclo(Arg-Ala-Asp-(D-Tyr)-Lys) is used in cell-based assays as a control for c(RGDyK) activity. Cells expressing integrin receptors are treated with the peptide to confirm that any observed effects are specific to the RGD motif. Standard cell culture conditions (37°C, 5% CO₂) with appropriate media are employed. Cell adhesion, migration, and signaling assays are commonly used to evaluate the specificity of integrin-mediated responses.
|
| Animal Protocol |
Cyclo(Arg-Ala-Asp-(D-Tyr)-Lys) may be used in animal studies as a negative control peptide to validate the specificity of c(RGDyK)-mediated effects in vivo. It is administered via appropriate routes, and endpoints such as tumor growth, angiogenesis, or inflammation are assessed. All procedures must comply with institutional animal care and use guidelines.
|
| ADME/Pharmacokinetics |
Specific pharmacokinetic data for Cyclo(Arg-Ala-Asp-(D-Tyr)-Lys) are not documented in the literature, as it is primarily used as a control peptide and not as a therapeutic agent. As a cyclic peptide, its stability and bioavailability may differ from linear peptides, but detailed PK parameters have not been reported. The compound is typically stored as a powder at -20°C and is soluble in water or buffer solutions.
|
| Toxicity/Toxicokinetics |
Cyclo(Arg-Ala-Asp-(D-Tyr)-Lys) is intended for research use only and is not approved for human therapeutic applications. As a control peptide, comprehensive toxicological data are not extensively documented. Standard safety precautions should be observed when handling this compound, including the use of appropriate personal protective equipment. The compound should be handled in well-ventilated areas with proper waste disposal procedures.
|
| References |
[1]. Notni J, et al. Be spoilt for choice with radiolabelled RGD peptides: preclinical evaluation of ⁶⁸Ga-TRAP(RGD)₃. Nucl Med Biol. 2013 Jan;40(1):33-41.
|
| Additional Infomation |
Cyclo(Arg-Ala-Asp-(D-Tyr)-Lys) (c(RADyK)) (CAS#: 1193347-53-3) has a molecular formula of C₂₈H₄₃N₉O₈ and a molecular weight of 633.70 g/mol. It is a cyclic peptide control for c(RGDyK) with the sequence cyclo(Arg-Ala-Asp-DTyr-Lys). The compound is used as a biochemical assay reagent to validate integrin-mediated effects. It is not a drug and has not undergone clinical trials.
|
| Molecular Formula |
C28H43N9O8
|
|---|---|
| Exact Mass |
633.323
|
| CAS # |
1193347-53-3
|
| PubChem CID |
131676703
|
| Sequence |
Cyclo(Arg-Ala-Asp-{d-Tyr}-Lys)Cyclo(RAD-{d-Tyr}-K)
|
| SequenceShortening |
Cyclo(RAD-{d-Tyr}-K)
|
| Appearance |
Typically exists as solid at room temperature
|
| Density |
1.5±0.1 g/cm3
|
| Index of Refraction |
1.669
|
| LogP |
-3.48
|
| Hydrogen Bond Donor Count |
10
|
| Hydrogen Bond Acceptor Count |
10
|
| Rotatable Bond Count |
12
|
| Heavy Atom Count |
45
|
| Complexity |
1080
|
| Defined Atom Stereocenter Count |
5
|
| SMILES |
O=C1[C@H](CCCCN)NC([C@@H](CC2C=CC(=CC=2)O)NC([C@H](CC(=O)O)NC([C@H](C)NC([C@H](CCC/N=C(\N)/N)N1)=O)=O)=O)=O
|
| InChi Key |
FAILKIOFKCFNBU-NVYAHWSDSA-N
|
| InChi Code |
InChI=1S/C28H43N9O8/c1-15-23(41)36-21(14-22(39)40)27(45)37-20(13-16-7-9-17(38)10-8-16)26(44)35-18(5-2-3-11-29)25(43)34-19(24(42)33-15)6-4-12-32-28(30)31/h7-10,15,18-21,38H,2-6,11-14,29H2,1H3,(H,33,42)(H,34,43)(H,35,44)(H,36,41)(H,37,45)(H,39,40)(H4,30,31,32)/t15-,18-,19-,20+,21+/m0/s1
|
| Chemical Name |
2-[(2R,5R,8S,11S,14S)-8-(4-aminobutyl)-11-[3-(diaminomethylideneamino)propyl]-5-[(4-hydroxyphenyl)methyl]-14-methyl-3,6,9,12,15-pentaoxo-1,4,7,10,13-pentazacyclopentadec-2-yl]acetic acid
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
